88
Participants
Start Date
July 22, 2016
Primary Completion Date
May 11, 2017
Study Completion Date
August 23, 2017
BAY1817080
Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
Placebo
Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
Itraconazole
Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
CRS Clinical Research Services Berlin GmbH, Berlin
Lead Sponsor
Bayer
INDUSTRY